Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed pancreatic cancer (aspiration biopsy by fine needle \[PAAF\] by USE or biopsy guide by ECO-CT). It is mandatory the diagnostic by USE and will recommend the aspiration biopsy with this technique
Tumoural volume by TAC \< 500 cc
Aged 18 to 75 years inclusive
Eastern Cooperative Oncology Group (ECOG) performance status (PS) £ 1
Life-expectancy of more than 12 weeks
Women of child-bearing potential must be willing to practice reliable methods of birth control to prevent pregnancy
You may not be if
Previous radiotherapy or chemotherapy for malignant disease
Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L), platelets less than 100 x 109/L or haemoglobin less than 9 mg/dL; Prothrombin time (PT) less than 50%; Serum bilirubin greater than 2.5 times the upper limit of reference range (ULRR; Creatinine clearance less than 45 mL/min; ALT or AST greater than 2.5 times the ULRR
Active dermatoses (e.g. psoriasis, eczema)
Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, or drugs with known corneal toxicity
Known, severe hypersensitivity to ZD1839 or any of the excipients of this product
Clareo Health | IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
